Lynparza

FDA Approves New Prostate Cancer Treatment From AstraZeneca and Merck
FDA Approves New Prostate Cancer Treatment From AstraZeneca and Merck
Motley Fool
AstraZeneca
Merck
Lynparza
prostate cancer
FDA
Flag link:
AstraZeneca, Merck's star PARP inhibitor Lynparza expands reach in ovarian cancer with new US approval
AstraZeneca, Merck's star PARP inhibitor Lynparza expands reach in ovarian cancer with new US approval
Endpoints
AstraZeneca
Merck
Lynparza
ovarian cancer
Flag link:
From Gilead To AstraZeneca, Investors Should Watch These Biotech Giants Right Now
From Gilead To AstraZeneca, Investors Should Watch These Biotech Giants Right Now
Motley Fool
FDA
drug approvals
Gilead Sciences
remdesivir
AstraZeneca
Merck
Lynparza
Clovis Oncology
Rubraca
Bristol-Myers Squibb
Opdivo
Yervoy
Flag link:
Go or no go? Oncology dominates upcoming decisions
Go or no go? Oncology dominates upcoming decisions
EP Vantage
FDA
oncology
AstraZeneca
Lynparza
ovarian cancer
prostate cancer
Bristol-Myers Squibb
Opdivo
lung cancer
Flag link:
Positive Prostate Cancer Results for Lynparza Are Bad News for Clovis Oncology
Positive Prostate Cancer Results for Lynparza Are Bad News for Clovis Oncology
Motley Fool
Clovis Oncology
Rubraca
AstraZeneca
Merck
Lynparza
prostate cancer
Flag link:
AstraZeneca and Merck's Lynparza Improves Survival in Prostate Cancer with Specific Repair Gene Mutations
AstraZeneca and Merck's Lynparza Improves Survival in Prostate Cancer with Specific Repair Gene Mutations
BioSpace
AstraZeneca
Merck
clinical trials
Lynparza
metastatic castration-resistant prostate cancer
prostate cancer
Flag link:
AstraZeneca and Merck's string of Lynparza successes ends in ovarian cancer
AstraZeneca and Merck's string of Lynparza successes ends in ovarian cancer
BioPharma Dive
AstraZeneca
Merck
cediranib
ovarian cancer
clinical trials
Lynparza
Flag link:
AZ and Merck, racing against Glaxo, nab Lynparza 'priority' boost in ovarian cancer
AZ and Merck, racing against Glaxo, nab Lynparza 'priority' boost in ovarian cancer
Fierce Pharma
AstraZeneca
Merck
GSK
Lynparza
ovarian cancer
FDA
priority review
Zejula
Flag link:
FDA Approves New Pancreatic Treatment Found To Double Time Patients Live Without Disease Progression
FDA Approves New Pancreatic Treatment Found To Double Time Patients Live Without Disease Progression
Forbes
FDA
Lynparza
AstraZeneca
pancreatic cancer
Flag link:
FDA Approves AstraZeneca and Merck's Lynparza for Pancreatic Cancer
FDA Approves AstraZeneca and Merck's Lynparza for Pancreatic Cancer
BioSpace
AstraZeneca
Merck
Lynparza
pancreatic cancer
FDA
Flag link:
AZ, Merck's Lynparza narrowly snags FDA panel backing in pancreatic cancer
AZ, Merck's Lynparza narrowly snags FDA panel backing in pancreatic cancer
Fierce Pharma
AstraZeneca
Merck
Lynparza
pancreatic cancer
FDA
advisory panels
Flag link:
Is AZ, Merck's Lynparza approvable in pancreatic cancer sans survival benefit? FDA's about to decide
Is AZ, Merck's Lynparza approvable in pancreatic cancer sans survival benefit? FDA's about to decide
Fierce Pharma
AstraZeneca
Merck
Lynparza
FDA
BRCA-mutated pancreatic cancer
pancreatic cancer
Flag link:
Separate GSK, AstraZeneca trial results may widen ovarian cancer drug use
Separate GSK, AstraZeneca trial results may widen ovarian cancer drug use
Yahoo/Reuters
GSK
AstraZeneca
ESMO
ovarianc cancer
PARP inhibitors
Lynparza
Zejula
Flag link:
AstraZeneca strengthens lead in PARP drug class
AstraZeneca strengthens lead in PARP drug class
Biopharma Dive
AstraZeneca
Merck
Lynparza
ovarian cancer
PARP inhibitors
veliparib
Flag link:
ESMO: AZ, Merck's Lynparza chases Avastin combo nod with big ovarian cancer win
ESMO: AZ, Merck's Lynparza chases Avastin combo nod with big ovarian cancer win
Fierce Pharma
Roche
Avastin
ovarian cancer
AstraZeneca
Merck
Lynparza
ESMO
Flag link:
GSK and AstraZeneca's PARP Inhibitors Will Flex Their Muscles at ESMO
GSK and AstraZeneca's PARP Inhibitors Will Flex Their Muscles at ESMO
BioSpace
GSK
AstraZeneca
PARP inhibitors
ESMO
Lynparza
Zejula
Flag link:
ESMO 2019 preview – PARPs on parade
ESMO 2019 preview – PARPs on parade
EP Vantage
ESMO
PARP inhibitors
Lynparza
AstraZeneca
ovarian cancer
GSK
Zejula
Flag link:
AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatment
AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatment
Pharmaforum
AstraZeneca
Merck
Lynparza
clinical trials
advanced ovarian cancer
ovarian cancer
Calquence
Flag link:
AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis
AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis
Yahoo/Benzinga
AstraZeneca
Clovis Oncology
prostate cancer
Lynparza
Flag link:
AstraZeneca cancer drugs build as primary care shrinks
AstraZeneca cancer drugs build as primary care shrinks
Biopharma Dive
AstraZeneca
cancer
oncology
primary care
Tagrisso
Symbicort
Lynparza
Flag link:

Pages